Insulin glulisine

DB01309ApprovedProtein Based TherapiesBlood Glucose Lowering AgentsInsulinInsulin Analog

Insulin glulisine is a short-acting form of insulin used for glycemic control in type 1 and type 2 diabetes mellitus. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.

Mechanism
Curator reviewed
Primary indication
Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.Curator reviewed · 4 structured indications
Formula / weight
C258H384N64O78S6 · 5823.0 Da
First approval
Canada, 2006 · United States, 2009 · European Union, 2016
Also known as
Insulin Glulisine (recombinant DNA origin) · Insulin glulisine recombinant
Code names
HMR-1964
Brand names
  • Apidra

Resolves to

What you can answer from here — as of July 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
799Drug interactionsStructured to mechanism, not free text
Sign in
45Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
89Marketed productsAcross 9 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 18 drug categories
Sign in
17+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Insulin glulisine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account